From €4342EUR$4,900USD£3,739GBP
- Report
- May 2025
- 182 Pages
Global
From €3142EUR$3,545USD£2,705GBP
€3491EUR$3,939USD£3,006GBP
- Report
- July 2025
- 375 Pages
Global
From €5184EUR$5,850USD£4,465GBP
- Report
- February 2025
- 185 Pages
Global
From €3390EUR$3,825USD£2,919GBP
€3988EUR$4,500USD£3,434GBP
- Report
- November 2024
- 150 Pages
Global
From €2880EUR$3,250USD£2,480GBP
€4298EUR$4,850USD£3,701GBP
- Report
- December 2024
- 150 Pages
Global
From €3500EUR$3,950USD£3,014GBP
- Report
- April 2021
- 269 Pages
Global
From €1108EUR$1,250USD£954GBP
€2215EUR$2,500USD£1,908GBP
- Report
- October 2023
- 145 Pages
Global
From €2791EUR$3,150USD£2,404GBP
- Report
- May 2024
- 67 Pages
South Africa
From €1994EUR$2,250USD£1,717GBP
- Report
- May 2024
- 78 Pages
North America
From €2614EUR$2,950USD£2,251GBP
- Report
- May 2024
- 86 Pages
Asia Pacific
From €3057EUR$3,450USD£2,633GBP
- Report
- March 2024
- 60 Pages
From €2614EUR$2,950USD£2,251GBP
- Report
- March 2024
- 65 Pages
Europe
From €3057EUR$3,450USD£2,633GBP
- Webinar
- August 2022
- 60 Minutes
Global
From €173EUR$195USD£149GBP
- Book
- April 2025
- 1024 Pages
- Book
- May 2018
- 872 Pages
- Book
- August 2013
- 462 Pages
Global

Attention Deficit Disorder (ADD) is a mental health disorder characterized by difficulty focusing, impulsivity, and hyperactivity. It is most commonly diagnosed in children, but can also affect adults. Symptoms of ADD can include difficulty paying attention, difficulty organizing tasks, restlessness, and impulsivity. Treatment for ADD typically includes medication, psychotherapy, and lifestyle changes.
The Attention Deficit Disorder market is a subset of the larger Mental Health market. It is a growing market, with an increasing number of people seeking treatment for ADD. The market is expected to continue to grow as more people become aware of the disorder and seek treatment.
Companies in the Attention Deficit Disorder market include Shire Pharmaceuticals, Novartis, and Eli Lilly. Other companies in the Mental Health market include Pfizer, Johnson & Johnson, and GlaxoSmithKline. Show Less Read more